BioNTech CEO sells 27,000 and 34,000 shares

The indirect holding includes 106,721 shares held for an individual's benefit under a trust arrangement, with voting but not dispositive power exercised by Medine GmbH.

Rhea-AI Filing Summary

BioNTech SE Chief Executive Officer Ugur Sahin reported direct sales of 27,000 ordinary shares on September 25, 2026, at $98.6882 per share, and 34,000 ordinary shares on September 28, 2026, at $98.4682 per share. Both sales were effected pursuant to a Rule 10b5-1 trading plan established June 3, 2026. As of September 25, 2026, 39,218,111 ordinary shares were held indirectly through Medine GmbH, including 106,721 held for an individual's benefit under a trust arrangement in which Medine GmbH has voting but not dispositive power.

Insider Trade Summary 10b5-1

Net Seller: 61,000 shares

Net Sell 3 txns

Insider Sahin Ugur

Role Chief Executive Officer

Sold 61,000 shs ($6.01M)

Type	Security	Shares	Price	Value
Sale	Ordinary Shares	34,000	$98.4682	$3.35M
Sale	Ordinary Shares	27,000	$98.6882	$2.66M
holding	Ordinary Shares F1	--	--	--

Holdings After Transaction: Ordinary Shares — 280,209 shares (Direct); Ordinary Shares — 39,218,111 shares (Indirect, See Footnote)

Footnotes (1)

1. F1. The ordinary shares are held by Medine GmbH. The reporting person is the sole shareholder of Medine GmbH. 106,721 of the ordinary shares noted herein are held for the benefit of an individual under a trust arrangement, pursuant to which Medine GmbH exercises voting power, but not dispositive power, over such ordinary shares for so long as such ordinary shares are held in trust. The reporting person may be deemed to beneficially own the ordinary shares held by Medine GmbH.

Key Figures

Ordinary shares sold: 27,000 shares Price per share: $98.6882 per share Ordinary shares sold: 34,000 shares +3 more

6 metrics

Ordinary shares sold 27,000 shares Direct sale on September 25, 2026

Price per share $98.6882 per share Direct sale on September 25, 2026

Ordinary shares sold 34,000 shares Direct sale on September 28, 2026

Price per share $98.4682 per share Direct sale on September 28, 2026

Indirect ordinary shares 39,218,111 shares Held through Medine GmbH as of September 25, 2026

Trust arrangement shares 106,721 shares Held for an individual's benefit under a trust arrangement

Key Terms

Rule 10b5-1 trading plan, dispositive power, beneficially own, trust arrangement

4 terms

Rule 10b5-1 trading plan regulatory

"pursuant to a Rule 10b5-1 trading plan"

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

dispositive power regulatory

"but not dispositive power"

Dispositive power is the authority to decide the final outcome of an asset, legal claim, contract, or corporate action — in effect the power to dispose of or resolve something. For investors it matters because whoever holds that authority can determine who gets paid, who controls an asset or vote, and how risks and returns are allocated; think of it like holding the key that lets you lock in the winner or loser in a deal.

beneficially own regulatory

"may be deemed to beneficially own"

Beneficially own means having the economic rights and risks of a security—such as the right to receive dividends, sell the shares, or profit from price changes—whether or not your name appears on the official share register. Think of it like renting a car: you use it and reap the benefits even if the title lists someone else. Investors care because beneficial ownership determines who truly controls value, must be disclosed under securities rules, and can signal potential influence or trading activity that affects a stock’s price.

trust arrangement regulatory

"held in trust"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What BNTX share sales did CEO Ugur Sahin report?

Ugur Sahin sold 27,000 ordinary shares directly on September 25, 2026, at $98.6882 per share, and 34,000 directly on September 28, 2026, at $98.4682 per share. Both sales were made under a Rule 10b5-1 trading plan established June 3, 2026.

What indirect BioNTech shares are associated with Ugur Sahin?

The indirect holding was 39,218,111 ordinary shares as of September 25, 2026, held by Medine GmbH, whose sole shareholder is Ugur Sahin. Of those, 106,721 shares were held for an individual's benefit under a trust arrangement; Medine GmbH exercised voting power but not dispositive power over them while they were held in trust. Sahin may be deemed to beneficially own shares held by Medine GmbH.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/28/2026 - 05:18 PM Accepted by SEC EDGAR 09/28/2026 - 05:16 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Sahin Ugur

(Last) (First) (Middle)

C/O BIONTECH SE

AN DER GOLDGRUBE 12

(Street)

MAINZ D-55131

(City) (State) (Zip)

GERMANY

(Country)

2. Issuer Name and Ticker or Trading Symbol
BioNTech SE [ BNTX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	X	10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Executive Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
09/25/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Ordinary Shares	09/25/2026		S		27,000	D	$98.6882	314,209	D
Ordinary Shares	09/28/2026		S		34,000	D	$98.4682	280,209	D
Ordinary Shares								39,218,111	I	See Footnote(1)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The ordinary shares are held by Medine GmbH. The reporting person is the sole shareholder of Medine GmbH. 106,721 of the ordinary shares noted herein are held for the benefit of an individual under a trust arrangement, pursuant to which Medine GmbH exercises voting power, but not dispositive power, over such ordinary shares for so long as such ordinary shares are held in trust. The reporting person may be deemed to beneficially own the ordinary shares held by Medine GmbH.

Remarks:

The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan established by the reporting person on June 3, 2026.

	/s/ Humza Bokhari, Attorney-in-Fact	09/28/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)